Literature DB >> 10618420

The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions.

T Murakami1, E O Freed.   

Abstract

Lentiviruses, including HIV-1, have transmembrane envelope (Env) glycoproteins with cytoplasmic tails that are quite long compared with those of other retroviruses. However, mainly because of the lack of biochemical studies performed in cell types that are targets for HIV-1 infection, no clear consensus exists regarding the function of the long lentiviral Env cytoplasmic tail in virus replication. In this report, we characterize the biological and biochemical properties of an HIV-1 mutant lacking the gp41 cytoplasmic tail. We find that the gp41 cytoplasmic tail is necessary for the efficient establishment of a productive, spreading infection in the majority of T cell lines tested, peripheral blood mononuclear cells, and monocyte-derived macrophages. Biochemical studies using a high-level, transient HIV-1 expression system based on pseudotyping with the vesicular stomatitis virus glycoprotein demonstrate that in HeLa and MT-4 cells, mutant Env incorporation into virions is reduced only 3-fold relative to wild type. In contrast, gp120 levels in virions produced from a number of other T cell lines and primary macrophages are reduced more than 10-fold by the gp41 truncation. The Env incorporation defect imposed by the cytoplasmic tail truncation is not the result of increased shedding of gp120 from virions or reduced cell-surface Env expression. These results demonstrate that in the majority of T cell lines, and in primary cell types that serve as natural targets for HIV-1 infection in vivo, the gp41 cytoplasmic tail is essential for efficient Env incorporation into virions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10618420      PMCID: PMC26665          DOI: 10.1073/pnas.97.1.343

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

1.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

2.  Rapid and efficient site-specific mutagenesis without phenotypic selection.

Authors:  T A Kunkel; J D Roberts; R A Zakour
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

3.  Alterations in cell membrane permeability by the lentivirus lytic peptide (LLP-1) of HIV-1 transmembrane protein.

Authors:  M A Miller; M W Cloyd; J Liebmann; C R Rinaldo; K R Islam; S Z Wang; T A Mietzner; R C Montelaro
Journal:  Virology       Date:  1993-09       Impact factor: 3.616

4.  Direct interaction between the envelope and matrix proteins of HIV-1.

Authors:  P Cosson
Journal:  EMBO J       Date:  1996-11-01       Impact factor: 11.598

5.  Human immunodeficiency virus type 1 cell cycle control: Vpr is cytostatic and mediates G2 accumulation by a mechanism which differs from DNA damage checkpoint control.

Authors:  S R Bartz; M E Rogel; M Emerman
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

6.  Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity.

Authors:  J W Dubay; S J Roberts; B H Hahn; E Hunter
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

7.  Cytosolic domain of the human immunodeficiency virus envelope glycoproteins binds to calmodulin and inhibits calmodulin-regulated proteins.

Authors:  S K Srinivas; R V Srinivas; G M Anantharamaiah; R W Compans; J P Segrest
Journal:  J Biol Chem       Date:  1993-10-25       Impact factor: 5.157

8.  Incorporation of pseudorabies virus gD into human immunodeficiency virus type 1 Gag particles produced in baculovirus-infected cells.

Authors:  L Garnier; M Ravallec; P Blanchard; H Chaabihi; J P Bossy; G Devauchelle; A Jestin; M Cerutti
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

9.  Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection.

Authors:  E O Freed; G Englund; M A Martin
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

10.  Rescue of human immunodeficiency virus type 1 matrix protein mutants by envelope glycoproteins with short cytoplasmic domains.

Authors:  F Mammano; E Kondo; J Sodroski; A Bukovsky; H G Göttlinger
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

View more
  157 in total

1.  Mutational analysis of conserved domains within the cytoplasmic tail of gp41 from human immunodeficiency virus type 1: effects on glycoprotein incorporation and infectivity.

Authors:  S C Piller; J W Dubay; C A Derdeyn; E Hunter
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  A leucine zipper motif in the cytoplasmic domain of gp41 is required for HIV-1 replication and pathogenesis in vivo.

Authors:  S M Kao; E D Miller; L Su
Journal:  Virology       Date:  2001-10-25       Impact factor: 3.616

3.  Cellular membrane-binding ability of the C-terminal cytoplasmic domain of human immunodeficiency virus type 1 envelope transmembrane protein gp41.

Authors:  S S Chen; S F Lee; C T Wang
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

4.  Structural flexibility and functional valence of CD4-IgG2 (PRO 542): potential for cross-linking human immunodeficiency virus type 1 envelope spikes.

Authors:  P Zhu; W C Olson; K H Roux
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

5.  Mutation of the dominant endocytosis motif in human immunodeficiency virus type 1 gp41 can complement matrix mutations without increasing Env incorporation.

Authors:  John T West; Sally K Weldon; Stephanie Wyss; Xiaoxu Lin; Qin Yu; Markus Thali; Eric Hunter
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

6.  Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein.

Authors:  Terri G Edwards; Stéphanie Wyss; Jacqueline D Reeves; Susan Zolla-Pazner; James A Hoxie; Robert W Doms; Frédéric Baribaud
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

7.  Lipid rafts and pseudotyping.

Authors:  W F Pickl; F X Pimentel-Muiños; B Seed
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

8.  HIV-1 Envelope Glycoprotein Trafficking through the Endosomal Recycling Compartment Is Required for Particle Incorporation.

Authors:  Junghwa Kirschman; Mingli Qi; Lingmei Ding; Jason Hammonds; Krista Dienger-Stambaugh; Jaang-Jiun Wang; Lynne A Lapierre; James R Goldenring; Paul Spearman
Journal:  J Virol       Date:  2018-02-12       Impact factor: 5.103

9.  Reevaluation of the requirement for TIP47 in human immunodeficiency virus type 1 envelope glycoprotein incorporation.

Authors:  Mary Ann Checkley; Benjamin G Luttge; Peter Y Mercredi; Sampson K Kyere; Justin Donlan; Tsutomu Murakami; Michael F Summers; Simon Cocklin; Eric O Freed
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

10.  Oregano Oil and Its Principal Component, Carvacrol, Inhibit HIV-1 Fusion into Target Cells.

Authors:  S Mediouni; J A Jablonski; S Tsuda; A Barsamian; C Kessing; A Richard; A Biswas; F Toledo; V M Andrade; Y Even; M Stevenson; T Tellinghuisen; H Choe; M Cameron; T D Bannister; S T Valente
Journal:  J Virol       Date:  2020-07-16       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.